SCHEMBL1918921

SCHEMBL1918921

Cc1nc2c(C)cc(-c3ccccc3)cc2[nH]1

nearest known ligand 0.64

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 17/20 0.64
RPS6KA3 P51812 1/20 0.53
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12532869 0.81 RPS6KA3 (0.48) DHODHRPS6KA3SMN1; SMN2
SCHEMBL1918303 0.80 DHODH (0.47) DHODHRPS6KA3
SCHEMBL21974417 0.80 DHODH (0.97) DHODH
SCHEMBL6456171 0.79 ADORA3 (0.46) DHODHRPS6KA3KDM4E
SCHEMBL20482586 0.79 DHODH (1.00) DHODH
SCHEMBL1918938 0.77 DHODH (0.45) DHODHRPS6KA3KDM4E
SCHEMBL31366160 0.76 MEN1 (0.51) DHODHKDM4EHPGDSMN1; SMN2
SCHEMBL20482813 0.74 DHODH (0.76) DHODH
SCHEMBL30572573 0.74 RAB9A (0.67) DHODHKDM4EHPGDSMN1; SMN2
SCHEMBL6881507 0.74 RAB9A (0.67) DHODHKDM4EHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3081213-B1 TRICYCLIC COMPOUND KYOWA KIRIN CO LTD (JP) 2020-04-01 EP disclosed
US-9475805-B2 Tricyclic compound KYOWA HAKKO KIRIN CO., LTD. (JP) 2016-10-25 US disclosed
EP-3081213-A1 TRICYCLIC COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2016-10-19 EP disclosed
US-20150291587-A1 TRICYCLIC COMPOUND KYOWA KIRIN CO., LTD. (JP) 2015-10-15 US disclosed
US-20130267711-A1 TRICYCLIC COMPOUND KYOWA HAKKO KIRIN CO LTD (JP) 2013-10-10 US disclosed
US-8486980-B2 Tricyclic compound KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-07-16 US disclosed
US-20110201640-A1 TRICYCLIC COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-08-18 US disclosed
US-20110201640-A1 TRICYCLIC COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-08-18 US disclosed
EP-2327690-A1 TRICYCLIC COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2011-06-01 EP disclosed
EP-2327690-A1 TRICYCLIC COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2011-06-01 EP disclosed
WO-2010016549-A1 TRICYCLIC COMPOUND 協和発酵キリン株式会社 (JP) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150291587-A1 TRICYCLIC COMPOUND PPARA, PPARG, PPARD DHODH 4285/4885RPS6KA3 3328/4885KDM4E 2084/4885
US-20130267711-A1 TRICYCLIC COMPOUND PPARA, PPARG, PPARD DHODH 4285/4885RPS6KA3 3328/4885KDM4E 2084/4885
US-20110201640-A1 TRICYCLIC COMPOUND PPARG, PPARA, PPARD DHODH 4143/4885RPS6KA3 3138/4885KDM4E 1708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.